Biology, Significance and Immune Signaling of Mucin 1 in Hepatocellular Carcinoma.

Kumar, Ayana R; Devan, Aswathy R; Nair, Bhagyalakshmi; Nair, Reshma Ravindran; Nath, Lekshmi R

Kumar, Ayana R; Devan, Aswathy R; Nair, Bhagyalakshmi; Nair, Reshma Ravindran; Nath, Lekshmi R.

Afiliação

Kumar AR; Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi-682041, Kerala, India.
Devan AR; Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi-682041, Kerala, India.
Nair B; Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi-682041, Kerala, India.
Nair RR; Wellcome Centre for Cell Biology, University of Edinburgh, Scotland, United Kingdom.
Nath LR; Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi-682041, Kerala, India.

Curr Cancer Drug Targets ; 22(9): 725-740, 2022.

Article em En | MEDLINE | ID: mdl-35301949

Assuntos

Carcinoma Hepatocelular; Neoplasias Hepáticas; Antígenos de Neoplasias; Biologia; Carcinoma Hepatocelular/patologia; Humanos; Imunoterapia/métodos; Neoplasias Hepáticas/patologia; Mucina-1

Palavras-chave

MUC 1; aberrant glycosylation; hepatocellular carcinoma; highly glycosylated tumor-associated antigen (TAA); immune signaling; immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Curr Cancer Drug Targets Assunto da revista: ANTINEOPLASICOS / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Índia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google